Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis

Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira,
                 Karyopharm, Revance, Pluristem, and Sunesis

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 11, 2014

NEW YORK, March 11, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Hospira Inc.
(NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance
Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ:
PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth
members receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register

--

Hospira Inc. Analyst Notes

On March 4, 2014, Hospira Inc. (Hospira) announced the appointment of David J.
Endicott as President, Hospira Medical Devices, with effect from March 10,
2014. According to Hospira, in this role, Endicott will be responsible for
establishing a fully integrated device organization - leading the commercial,
research and development, manufacturing and related support functions to
continue to advance the Company's product pipeline, execute its device
strategy and ultimately drive global growth. F. Michael Ball, CEO of Hospira,
commented, "David is an accomplished global leader with more than 25 years of
industry experience - 15+ of those where I had the privilege of working with
him directly and had an opportunity to see firsthand his proven ability to
define, implement and manage sustainable process, organizational and cultural
change. With his impressive track record in delivering strong results across
all business functions, we're confident David will successfully lead our dual
imperatives to execute our device strategy and drive global growth." The full
analyst notes on Hospira Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03112014/HSP/report.pdf

--

Karyopharm Therapeutics, Inc. Analyst Notes

On March 5, 2014, Karyopharm Therapeutics, Inc. (Karyopharm) released its
full-year 2013 results and provided an update on its clinical development
plans. Karyopharm registered revenues of $0.4 million, down 39.0% YoY. The
Company posted an annual net loss of $33.9 million, compared to a net loss of
$15.9 million in full-year 2012. Diluted net loss came in at $5.59 per share,
compared to diluted net loss of $8.95 per share in full-year 2012. Michael
Kauffman, Karyopharm CEO, said, "2013 was has been a very important year for
Karyopharm, highlighted by robust clinical development activity focused on our
novel, first in class, orally active selective inhibitors of nuclear export
compounds, also called SINEs." Commenting on its future plans, Kauffman said,
"We have moved rapidly from discovery to the clinic. In 2014, we plan to
initiate three registration-directed trials in hematological indications and
to continue to broaden our solid tumor development activity. This foundation
positions us to continue our broad-based development plan to assess the
breadth of this novel anti-cancer mechanism." The full analyst notes on
Karyopharm Therapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03112014/KPTI/report.pdf

--

Revance Therapeutics, Inc. Analyst Notes

On March 5, 2014, Revance Therapeutics, Inc. (Revance) announced the
appointment of Angus C. Russell as Chairman of the Board, effective
immediately. Commenting on this, Dan Browne, President and CEO of Revance,
said, "Angus' impressive track record in the global biopharmaceutical industry
will bring significant value to Revance and its Board of Directors." Browne
added, "With his extensive experience growing companies commercially, I am
thrilled to have him as a partner as we continue to execute and build our
business." The full analyst notes on Revance Therapeutics, Inc. are available
to download free of charge at:

http://www.AnalystsReview.com/03112014/RVNC/report.pdf

--

Pluristem Therapeutics, Inc. Analyst Notes

On March 6, 2014, Pluristem Therapeutics, Inc. (Pluristem) announced that the
US Food and Drug Administration (FDA) has reviewed the Company's comparability
studies of its PLacental eXpanded (PLX) cell products and granted approval for
the manufacturing of these products in its new commercial-scale cell
manufacturing facility - which has the ability to efficiently produce
approximately150,000 doses of PLX cells annually. Zami Aberman, Chairman and
CEO of Pluristem, stated, "Knowing that the 'Process is the Product' in cell
therapy, we have established our leadership position in the industry by
focusing on our 3D commercial scale cell manufacturing processes. To be a
successful company in the industry, we believe it is imperative to possess and
control the manufacturing processes we have developed at Pluristem. We believe
this FDA approval, combined with the approval given by the
Paul-Ehrlich-Institute (PEI) of Germany announced on January 23, 2014, is an
indication that these regulatory bodies see our proprietary 3D manufacturing
process as a valid and sustainable commercial scale solution for potential
cell therapies." The full analyst notes on Pluristem Therapeutics, Inc. are
available to download free of charge at:

http://www.AnalystsReview.com/03112014/PSTI/report.pdf

--

Sunesis Pharmaceuticals, Inc. Analyst Notes

On March 6, 2014, Sunesis Pharmaceuticals, Inc. (Sunesis) released its Q4 2013
and full year 2013 results. During the quarter, Sunesis registered total
revenues of $2.0 million, flat as compared to Q4 2012, while full-year 2013
reported total revenues stood at $8.0 million, up 111.9% YoY. The Company
posted quarterly net loss of $7.2 million, compared to net loss of $4.1
million in Q4 2012, and annual net loss of $34.6 million, compared to net loss
of $44.0 million in full year 2012. Further, Sunesis reported quarterly
diluted net loss of $0.15 per share, compared to diluted net loss of $0.20 per
share in Q4 2012, and annual diluted net loss of $0.66 per share, compared to
diluted net loss of $0.91 per share in full year 2012. The full analyst notes
on Sunesis Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03112014/SNSS/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES:

  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@AnalystsReview.com.
  oFor any urgent concerns or inquiries, please contact us at
    compliance@AnalystsReview.com.
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research@AnalystsReview.com
    for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts Review

Contact: CONTACT PERSON: Adam Redford CONTACT PHONE: +852-8191-3972
 
Press spacebar to pause and continue. Press esc to stop.